Microbial Risk Analysis, published by Elsevier, is a pivotal academic journal specializing in the intersection of epidemiology, infectious diseases, and medical microbiology. With an ISSN of 2352-3522 and an E-ISSN of 2352-3530, this journal has been contributing to the field since its inception in 2016 and continues to invite groundbreaking research as it converges through 2024. With a respectable impact factor, Microbial Risk Analysis holds a Q3 designation in key categories, showcasing its credibility with ranks such as #48 in Epidemiology and #124 in Infectious Diseases according to Scopus. The journal serves as an essential platform for researchers, professionals, and students alike, aiming to enhance understanding of microbial risks and their public health implications. Although it operates under a subscription model, its contents remain accessible to a broad range of interdisciplinary scholars dedicated to advancing microbial research. For those at the forefront of epidemiological and infectious disease studies, Microbial Risk Analysis represents a crucial resource for disseminating knowledge and fostering collaboration.

Biosafety and Health is a leading peer-reviewed journal published by ELSEVIER, dedicated to advancing knowledge and practice in the fields of biotechnology, infectious diseases, microbiology, and public health. With an ISSN of 2096-6962 and an E-ISSN of 2590-0536, this Open Access journal has been accessible to the global research community since 2019, fostering collaboration and innovation from its base in the Netherlands. Ranked Q2 in multiple categories according to the latest metrics, including Biotechnology and Microbiology (medical), it stands as a testament to high-quality, impactful research that influences clinical and environmental practices. The journal has achieved substantial recognition in various medical fields, ranking in the 88th percentile for Public Health, Environmental and Occupational Health, and the 78th percentile for Infectious Diseases. Researchers and practitioners seeking to contribute to this evolving domain are encouraged to submit their findings, as the journal aims to promote interdisciplinary dialogue and address pressing global health challenges.

VECTOR-BORNE AND ZOONOTIC DISEASES is a prominent journal dedicated to advancing research in the fields of infectious diseases, microbiology, and virology, published by Mary Ann Liebert, Inc. With a rich history spanning from 2001 to 2024, this journal plays a critical role in disseminating cutting-edge research and insights regarding diseases transmitted by vectors and zoonotic pathogens. It has achieved notable rankings, including Q2 in the Infectious Diseases category and Q3 in both Microbiology and Virology as of 2023. The journal's emphasis on quality and relevance is further underscored by its established position—ranked 151st in Infectious Diseases and within the 43rd percentile in Virology according to Scopus. Although not an open-access journal, the publication ensures that its findings reach a broad audience of researchers, professionals, and students dedicated to tackling the challenges posed by these critical health issues. By providing a platform for innovative studies and discussions, VECTOR-BORNE AND ZOONOTIC DISEASES remains an essential resource for those at the forefront of disease research and public health strategies.

RISK ANALYSIS is a premier journal published by Wiley, focusing on the critical intersection of safety, risk, reliability, and quality within the fields of engineering and physiology. With a strong standing reflected in its Q1 category ranking in Safety, Risk, Reliability and Quality and Q2 in Physiology (medical), this journal is a vital resource for researchers, professionals, and students eager to stay informed on the latest methodologies, theories, and applications surrounding risk assessment and management. Since its inception in 1981, RISK ANALYSIS has been instrumental in shaping the discourse in its fields, garnering a robust reputation verified by its high rankings on Scopus, where it is positioned in the 85th percentile in Safety and the 77th percentile in Medicine. Though it does not currently offer Open Access options, the journal remains essential for those committed to advancing their understanding of risks associated with complex systems. For more insights, RISK ANALYSIS is available to readers throughout its converged years extending to 2024, solidifying its role as a foundational journal for impactful research.

IJID Regions is a pioneering open access journal published by Elsevier, focusing on the critical fields of epidemiology, infectious diseases, and public health. Established in 2021, the journal aims to provide a platform for disseminating high-quality, innovative research that addresses pressing health issues and informs evidence-based practices in communities around the globe. With its impact factors reflecting a Tier Q2 and Q3 ranking in various medical subcategories on the Scopus platform, IJID Regions is positioned as a valuable resource for researchers, health professionals, and policy-makers striving to enhance public health outcomes. This journal not only champions open access since its inception, promoting the free flow of information, but also welcomes contributions that shed light on contemporary challenges in environmental and occupational health. Its commitment to fostering dialogue and collaboration in the health sciences is paramount, making it an essential read for those engaged in advancing public health knowledge and initiatives.

The Lancet Regional Health-Europe is a prestigious academic journal published by Elsevier, dedicated to advancing research in the fields of Health Policy, Internal Medicine, and Oncology. As part of a reputable series that focuses on regional health issues, it aims to publish high-quality, peer-reviewed articles that contribute to the understanding and improvement of health systems across Europe. With an impressive impact factor reflected in its Q1 quartile rankings for 2023—ranking #2 in Health Policy, #8 in Internal Medicine, and #22 in Oncology—it is recognized for its significant contribution to cutting-edge research. The journal offers open access options, ensuring that findings are widely disseminated and accessible to researchers, healthcare professionals, and policy-makers alike. By fostering collaboration and interdisciplinary discourse, The Lancet Regional Health-Europe serves as an essential platform for innovative solutions and strategies in health care that address the unique challenges faced within the European context, making it an invaluable resource for academics and practitioners dedicated to public health advancement.

Open Forum Infectious Diseases (ISSN: 2328-8957; E-ISSN: 2328-8957) is a leading open-access journal published by Oxford University Press, dedicated to advancing the field of infectious diseases. Since its inception in 2014, the journal has provided a platform for researchers to disseminate impactful findings in a rapidly evolving domain, achieving a remarkable Q1 ranking in both the Infectious Diseases and Oncology categories as of 2023. The journal encourages rigorous and innovative research, contributing significantly to global health discussions and informing best practices in clinical settings. As an open-access journal, it ensures that its content is accessible to a wide audience, fostering collaboration and knowledge sharing among researchers, professionals, and students alike. Positioned in the heart of the United States, Open Forum Infectious Diseases serves as a critical resource for the academic community, and its continued commitment to quality and relevance secures its status as an essential publication in the field.

Emerging Microbes & Infections is a premier open access journal, published by Taylor & Francis Ltd since 2012, dedicated to advancing the understanding of microbial infections and their implications in human health. With an impressive Q1 ranking across multiple categories—including Drug Discovery, Epidemiology, Immunology, and Infectious Diseases—this journal is at the forefront of research in the microbiological sciences. Covering a diverse range of topics, it serves as a vital resource for researchers, healthcare professionals, and students alike. The journal's commitment to open access ensures worldwide dissemination of cutting-edge findings, fostering collaboration and innovation in tackling challenges posed by emerging infections. As part of the thriving academic community in the United Kingdom, Emerging Microbes & Infections plays a crucial role in shaping the future of infectious disease research and public health.

Microbiology Australia is a prominent journal published by CSIRO PUBLISHING, focusing on the diverse and rapidly evolving field of microbiology. Since its transition to Open Access in 2021, it has broadened its accessibility, fostering greater dissemination of research findings among scholars and practitioners. The journal features a range of topics that are pivotal for understanding microbial systems in applied microbiology, medical microbiology, public health, and environmental applications. Despite its current categorization in the Q4 quartile across several categories, it remains an essential platform for emerging research and innovative methodologies. Researchers and professionals can benefit from the journal's commitment to enriching the global discourse on microbiological advancements. With its ISSN 1324-4272 and E-ISSN 2201-9189, Microbiology Australia caters to a wide audience in Australia and beyond, making significant strides in bridging the gap between research and practical applications in microbiology.

Eurosurveillance is a prestigious journal dedicated to the field of epidemiology, public health, and infectious diseases, published by the European Centre for Disease Prevention and Control since 1996. With an impressive Q1 ranking across various categories, including Epidemiology and Public Health, it consistently stands at the forefront of research dissemination, making it an invaluable resource for researchers, professionals, and students alike. The journal boasts an outstanding reputation, as evidenced by its Scopus rankings, where it ranks in the top 1% to 3% in multiple relevant categories. As an Open Access publication, Eurosurveillance ensures that vital findings are freely accessible to a global audience, fostering collaboration and innovation in the fight against infectious diseases. With a dedicated reach from 2001 to 2024, the journal addresses contemporary challenges in public health and virology, reinforcing its significance in shaping policies and research initiatives across the world.